MX2007011174A - Metodos y formulaciones de metformina para tratar constipacion cronica. - Google Patents
Metodos y formulaciones de metformina para tratar constipacion cronica.Info
- Publication number
- MX2007011174A MX2007011174A MX2007011174A MX2007011174A MX2007011174A MX 2007011174 A MX2007011174 A MX 2007011174A MX 2007011174 A MX2007011174 A MX 2007011174A MX 2007011174 A MX2007011174 A MX 2007011174A MX 2007011174 A MX2007011174 A MX 2007011174A
- Authority
- MX
- Mexico
- Prior art keywords
- metformin
- methods
- formulations
- treating chronic
- chronic constipation
- Prior art date
Links
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 title abstract 5
- 229960003105 metformin Drugs 0.000 title abstract 5
- 206010010774 Constipation Diseases 0.000 title abstract 4
- 238000009472 formulation Methods 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 4
- 230000001684 chronic effect Effects 0.000 title abstract 3
- 238000010521 absorption reaction Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000002496 gastric effect Effects 0.000 abstract 1
- 239000004615 ingredient Substances 0.000 abstract 1
- 208000002551 irritable bowel syndrome Diseases 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- 230000009885 systemic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US66292005P | 2005-03-18 | 2005-03-18 | |
| PCT/IB2006/002233 WO2007007189A2 (en) | 2005-03-18 | 2006-03-16 | Metformin methods and formulations for treating chronic constipation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2007011174A true MX2007011174A (es) | 2008-02-11 |
Family
ID=37637555
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2007011174A MX2007011174A (es) | 2005-03-18 | 2006-03-16 | Metodos y formulaciones de metformina para tratar constipacion cronica. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20060222709A1 (https=) |
| EP (1) | EP1865939A2 (https=) |
| JP (1) | JP2008533127A (https=) |
| AU (1) | AU2006268003A1 (https=) |
| CA (1) | CA2599531A1 (https=) |
| IL (1) | IL185652A0 (https=) |
| MX (1) | MX2007011174A (https=) |
| NO (1) | NO20075344L (https=) |
| WO (1) | WO2007007189A2 (https=) |
| ZA (1) | ZA200707325B (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010062861A2 (en) * | 2008-11-26 | 2010-06-03 | Satiogen Pharmaceuticals, Inc. | Bile acid recycling inhibitors for treatment of obesity and diabetes |
| ES2552657T3 (es) | 2010-05-26 | 2015-12-01 | Satiogen Pharmaceuticals, Inc. | Inhibidores del reciclado de ácidos biliares y saciógenos para el tratamiento de diabetes, obesidad, y afecciones gastrointestinales inflamatorias |
| EP2661266B1 (en) * | 2011-01-07 | 2020-09-16 | Anji Pharma (US) LLC | Chemosensory receptor ligand-based therapies |
| US9572784B2 (en) | 2011-01-07 | 2017-02-21 | Elcelyx Therapeutics, Inc. | Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk |
| US11974971B2 (en) * | 2011-01-07 | 2024-05-07 | Anji Pharmaceuticals Inc. | Compositions and methods for treating metabolic disorders |
| US9480663B2 (en) | 2011-01-07 | 2016-11-01 | Elcelyx Therapeutics, Inc. | Biguanide compositions and methods of treating metabolic disorders |
| US11759441B2 (en) * | 2011-01-07 | 2023-09-19 | Anji Pharmaceuticals Inc. | Biguanide compositions and methods of treating metabolic disorders |
| US8796338B2 (en) | 2011-01-07 | 2014-08-05 | Elcelyx Therapeutics, Inc | Biguanide compositions and methods of treating metabolic disorders |
| US9211263B2 (en) | 2012-01-06 | 2015-12-15 | Elcelyx Therapeutics, Inc. | Compositions and methods of treating metabolic disorders |
| EP2599789A1 (en) * | 2011-12-01 | 2013-06-05 | Bergen Teknologioverføring AS | Marker and method for diagnosing diarrhea syndrome |
| EP2800562A2 (en) * | 2012-01-06 | 2014-11-12 | Elcelyx Therapeutics, Inc. | Compositions and methods for treating metabolic disorders |
| KR20190120430A (ko) * | 2012-01-06 | 2019-10-23 | 엘셀릭스 테라퓨틱스 인코포레이티드 | 바이구아나이드 조성물 및 대사 장애를 치료하는 방법 |
| HK1210825A1 (en) * | 2012-07-11 | 2016-05-06 | Elcelyx Therapeutics, Inc. | Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk |
| MX2015002210A (es) * | 2012-08-29 | 2015-05-08 | Salix Pharmaceuticals Inc | Composiciones laxantes y metodos para tratar estreñimiento y enfermedades y condiciones gastrointestinales relacionadas. |
| CN105101956B (zh) * | 2013-01-05 | 2018-12-07 | 埃尔舍利克斯治疗公司 | 包含双胍的延迟释放组合物 |
| CN104434846A (zh) * | 2014-11-17 | 2015-03-25 | 中国药科大学 | 盐酸二甲双胍肠溶缓释微丸及其制备方法 |
| TW201938147A (zh) * | 2017-12-18 | 2019-10-01 | 德商拜耳廠股份有限公司 | 阿卡波糖與甲福明之固定劑量組合錠劑配製物及其製法 |
| EP4045520A1 (en) | 2019-10-16 | 2022-08-24 | Bayer Aktiengesellschaft | Methods for the improved formation of acarbose |
| CN120152703A (zh) | 2022-11-07 | 2025-06-13 | 再青春生物医药股份有限公司 | 二甲双胍微型片剂 |
| CN119499228B (zh) * | 2023-08-22 | 2026-04-03 | 雅研(天津)生物医药科技中心(有限合伙) | 盐酸二甲双胍肠溶制剂 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AP1224A (en) * | 1998-03-19 | 2003-11-14 | Bristol Myers Squibb Co | Biphasic controlled release delivery system for high solubility pharmaceuticals and method. |
| CZ20011629A3 (cs) * | 1998-11-12 | 2001-12-12 | Smithkline Beecham Plc | Farmaceutický prostředek pro upravené uvolňování senzitizéru inzulínu a jiných antidiabetických přípravků |
| US6676966B1 (en) * | 2000-05-09 | 2004-01-13 | Intellipharmaceutics Corp. | Extended release metformin hydrochloride formulations |
| US6790459B1 (en) * | 2000-11-03 | 2004-09-14 | Andrx Labs, Llc | Methods for treating diabetes via administration of controlled release metformin |
| US7985422B2 (en) * | 2002-08-05 | 2011-07-26 | Torrent Pharmaceuticals Limited | Dosage form |
| US20060045865A1 (en) * | 2004-08-27 | 2006-03-02 | Spherics, Inc. | Controlled regional oral delivery |
-
2006
- 2006-03-15 US US11/375,399 patent/US20060222709A1/en not_active Abandoned
- 2006-03-16 CA CA002599531A patent/CA2599531A1/en not_active Abandoned
- 2006-03-16 WO PCT/IB2006/002233 patent/WO2007007189A2/en not_active Ceased
- 2006-03-16 JP JP2008501452A patent/JP2008533127A/ja active Pending
- 2006-03-16 MX MX2007011174A patent/MX2007011174A/es not_active Application Discontinuation
- 2006-03-16 AU AU2006268003A patent/AU2006268003A1/en not_active Abandoned
- 2006-03-16 EP EP06795261A patent/EP1865939A2/en not_active Withdrawn
-
2007
- 2007-08-29 ZA ZA200707325A patent/ZA200707325B/xx unknown
- 2007-09-02 IL IL185652A patent/IL185652A0/en unknown
- 2007-10-18 NO NO20075344A patent/NO20075344L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1865939A2 (en) | 2007-12-19 |
| NO20075344L (no) | 2007-10-18 |
| ZA200707325B (en) | 2009-03-25 |
| WO2007007189A3 (en) | 2007-04-26 |
| CA2599531A1 (en) | 2007-01-18 |
| IL185652A0 (en) | 2008-01-06 |
| JP2008533127A (ja) | 2008-08-21 |
| WO2007007189A2 (en) | 2007-01-18 |
| AU2006268003A1 (en) | 2007-01-18 |
| US20060222709A1 (en) | 2006-10-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2007011174A (es) | Metodos y formulaciones de metformina para tratar constipacion cronica. | |
| EP1834637A4 (en) | COMPOSITION FOR THE PREVENTION / TREATMENT OF DISEASES THROUGH FREE RADICALS | |
| WO2011005811A8 (en) | Combination therapy for the treatment of diabetes | |
| WO2004098589A8 (en) | 4- bromo - 5 - (2- chloro - benzoylamino) - 1h - pyrazole - 3 - carboxylic acid amide derivatives and related compounds as bradykinin b1 receptor antagonists for the treatment of inflammatory diseases | |
| WO2007044085A3 (en) | Heteroaryl compounds and their uses as therapeutic agents | |
| WO2009109613A3 (en) | 1-BENZYL-3-HYDROXYMETHYLINDAZOIιE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF DISEASES BASED ON THE EXPRESSION OF MCP-1, CX3CR1 | |
| NZ572049A (en) | Method for treatment of constipation-predominant irritable bowel syndrome | |
| TW200700093A (en) | Pharmaceutical composition for the treatment of cancer | |
| WO2009109616A3 (en) | 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cxrl and p40 | |
| WO2008144269A3 (en) | Methods for using vasopressin antagonists with anthracycline chemotherapy agents to reduce cardiotoxicity and/or improve survival | |
| MY147450A (en) | Pharmaceutical combination | |
| WO2007046868A3 (en) | Thiazolidine derivatives and their uses as therapeutic agents | |
| WO2009109654A8 (en) | 1-benzyl-3-hydr0xymethylindaz0le derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, and cx3cr1 | |
| WO2007046867A3 (en) | Piperidine derivatives and their uses as therapeutic agents | |
| WO2006093784A3 (en) | Dosage forms of antibiotics and combinations of antibiotics ans symptomatic relief agents | |
| NO20075393L (no) | Akarbosebaserte fremgangsmater og utforminger for behandling av kronisk forstoppelse | |
| WO2008070010A3 (en) | Hydroxylamine derivatives for the treatment of stroke | |
| WO2007145863A3 (en) | Sustained release formulation of naltrexone | |
| WO2006071775A3 (en) | Novel compounds useful for bradykinin b1 receptor antagonism | |
| WO2006125194A3 (en) | Piperazine derivatives and their uses as therapeutic agents | |
| WO2006125178A3 (en) | Tricyclic pyridazine compounds and their uses as therapeutic agents | |
| WO2008065144A3 (en) | Galenic formulations of organic compounds | |
| WO2006079077A3 (en) | Use of diltiazem or analogs thereof as modulators of ghrelin receptor | |
| WO2009061445A3 (en) | Use of immunomodulatory compounds for the treatment of disorders associated with endothelial dysfunction | |
| WO2007115020A3 (en) | Therapeutic prostaglandin compounds for the treatment of glaucoma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |